4.7 Article

Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma

Journal

FASEB JOURNAL
Volume 33, Issue 12, Pages 13476-13491

Publisher

WILEY
DOI: 10.1096/fj.201901075R

Keywords

GBM; ERR-beta; alternative splicing; cortactin; CLK

Funding

  1. U.S. National Institutes of Health/National Cancer Institute Grant (NIH/NCI) [R21 CA191444]
  2. Georgetown University Medical Center (GUMC) Dean for Research's Toulmin Pilot Project Award
  3. Partners in Research Breakthrough Award
  4. NIH/NCI [F99 CA234799]
  5. Medical Center Graduate Student Organization (MCGSO)
  6. Tumor Biology Training Grant [T32 CA009686]
  7. NIH/NCI Cancer Center Support Grant [P30 CA051008]
  8. [P50 CA108961]

Ask authors/readers for more resources

Glioblastoma (GBM; grade 4 glioma) is a highly aggressive and incurable tumor. GBM has recently been characterized as highly dependent on alternative splicing, a critical driver of tumor heterogeneity and plasticity. Estrogen-related receptor beta (ERR-beta) is an orphan nuclear receptor expressed in the brain, where alternative splicing of the 3' end of the pre-mRNA leads to the production of 3 validated ERR-beta protein products: ERR-beta short form (ERR-(beta sf), ERR-beta 2, and ERR-beta exon 10 deleted. Our prior studies have shown the ERR-beta isoform to play a role in G(2)/M cell cycle arrest and induction of apoptosis, in contrast to the function of the shorter ERR-beta 2 isoform in senescence and G1 cell cycle arrest. In this study, we sought to better define the role of the proapoptotic ERR-beta 2 isoform in GBM. We show that the ERR-beta 2 isoform is located not only in the nucleus but also in the cytoplasm. ERR-beta 2 suppresses GBM cell migration and interacts with the actin nucleation-promoting factor cortactin, and an ERR-beta agonist is able to remodel the actin cytoskeleton and similarly suppress GBM cell migration. We further show that inhibition of the splicing regulatory cdc2-like kinases in combination with an ERR-beta agonist shifts isoform expression in favor of ERR-beta 2 and potentiates inhibition of growth and migration in GBM cells and intracranial tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available